DiaMedica Therapeutics Inc.

NASDAQ (USD): DiaMedica Therapeutics Inc. (DMAC)

Last Price

6.41

Today's Change

+1.54 (31.62%)

Day's Change

4.75 - 6.41

Trading Volume

235,468

Profile
DMAC

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Dietrich John Pauls MBA Mr. Dietrich John Pauls MBA

Full Time Employees:  18 18

IPO Date:  2012-08-03 2012-08-03

CIK:  0001401040 0001401040

ISIN:  CA25253X2077 CA25253X2077

CUSIP:  25253X207 25253X207

Beta:  1.46 1.46

Last Dividend:  0.00 0.00

Dcf Diff:  6.28 6.28

Dcf:  0.13 0.13

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Address

Two Carlson Parkway,
Minneapolis, MN 55447, US

763 612 6755

http://www.diamedica.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment